KM Research Hub
← 返回论文库
已完成 入排:符合 图源:可得 入排置信度 0.98

Darolutamide in Combination With Androgen-Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer From the Phase III ARANOTE Trial.

Fred Saad, Egils Vjaters, Neal Shore, David Olmos, Nianzeng Xing, Andrea Juliana Pereira de Santana Gomes, Augusto Cesar de Andrade Mota, Pamela Salman, Mindaugas Jievaltas, Albertas Ulys, Maris Jakubovskis, Evgeny Kopyltsov, Weiqing Han, Liina Nevalaita, Isabella Testa, Marie-Aude Le Berre, Iris Kuss, Kunhi Parambath Haresh, ARANOTE Study Investigators

J Clin Oncol 42(36) 4271-4281

PMID39279580
PMCIDPMC11654448
DOI10.1200/JCO-24-01798
发表日期2024-09-16
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:图像复核确认至少一个 KM 面板含可见 No. at risk 表。
摘要

摘要

PURPOSE: For patients with metastatic hormone-sensitive prostate cancer (mHSPC), delaying progression to castration-resistant disease is important not only for overall survival (OS) but also for patients' quality of life. Darolutamide plus androgen-deprivation therapy (ADT) with docetaxel improved OS versus ADT and docetaxel in patients with mHSPC. The ARANOTE trial evaluated darolutamide and ADT without chemotherapy in patients with mHSPC. METHODS: In this global phase III trial, patients were randomly assigned 2:1 to receive darolutamide 600 mg twice daily or placebo, with concomitant ADT. The primary end point was radiological progression-free survival (rPFS). RESULTS: From March 2021 to August 2022, 669 patients were randomly assigned (darolutamide n = 446; placebo n = 223). At the primary cutoff date (June 7, 2024), darolutamide plus ADT significantly improved rPFS, reducing the risk of radiological progression or death by 46% versus placebo plus ADT (hazard ratio [HR], 0.54 [95% CI, 0.41 to 0.71]; P < .0001), with consistent benefits across subgroups, including high- and low-volume disease. OS results were suggestive of benefit with darolutamide versus placebo (HR, 0.81 [95% CI, 0.59 to 1.12]), and clinical benefits were seen across all other secondary end points, including delayed time to metastatic castration-resistant prostate cancer (HR, 0.40 [95% CI, 0.32 to 0.51]) and time to pain progression (HR, 0.72 [95% CI, 0.54 to 0.96]). Adverse events were similar in the two groups. Notably, the incidence of fatigue was lower in patients receiving darolutamide (5.6%) versus those receiving placebo (8.1%), and fewer patients receiving darolutamide (6.1%) versus placebo (9.0%) discontinued treatment because of adverse events. CONCLUSION: These results confirm the efficacy and tolerability of darolutamide plus ADT in patients with mHSPC, demonstrating clinically and statistically significant improvement in rPFS and a favorable safety profile consistent with prior phase III darolutamide trials.

KM 提取结果

3 个 Figure · 4 个 KM 面板

进入结果中心
KM Figure1 个面板

FIG 2.

FIG 2. rPFS (full analysis set). (A) Kaplan-Meier estimates and (B) subgroup analyses. The HR and 95% CI were calculated using the Cox regression model stratified by the presence of visceral metastases and prior therapy. Subgroup analyses of rPFS provide HRs and 95% CIs obtained from univariate analysis using an unstratified Cox regression model. ADT, androgen-deprivation therapy; ECOG PS, Eastern Cooperative Oncology Group performance status; HR, hazard ratio; NR, not reached; PSA, prostate-specific antigen; RoW, rest of the world; rPFS, radiological progression-free survival.

A

rPFS

FIG 2. · Panel A

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel A 是同一 FIG 2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似图例或人工水平线:轨迹出现不合理的共同平台疑似图例或人工水平线:轨迹出现不合理的共同平台
查看结果
KM Figure2 个面板

FIG 3.

FIG 3. Additional secondary time-to-event end points (full analysis set). (A) Time to metastatic castration-resistant prostate cancer and (B) time to PSA progression. Hazard ratios and 95% CIs were calculated using the Cox regression model stratified by the presence of visceral metastases and prior therapy. ADT, androgen-deprivation therapy; NR, not reached; PSA, prostate-specific antigen.

A

Time to metastatic castration-resistant prostate cancer

FIG 3. · Panel A

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel A 是同一 FIG 3. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 1:short span
查看结果
B

Time to PSA progression

FIG 3. · Panel B

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel B 是同一 FIG 3. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似图例或人工水平线:轨迹出现不合理的共同平台疑似图例或人工水平线:轨迹出现不合理的共同平台
查看结果
KM Figure1 个面板

FIG A1.

FIG A1. OS (full analysis set). (A) Kaplan–Meier estimates and (B) subgroup analyses. The HR and 95% CI were calculated using the Cox regression model stratified by the presence of visceral metastases and prior therapy. Subgroup analyses of OS provide HRs and 95% CIs obtained from univariate analysis using an unstratified Cox regression model. ADT, androgen-deprivation therapy; ECOG PS, Eastern Cooperative Oncology Group performance status; HR, hazard ratio; NR, not reached; OS, overall survival; PSA prostate-specific antigen; RoW, rest of the world.

A

overall survival

FIG A1. · Panel A

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel A 是同一 FIG A1. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似图例或人工水平线:轨迹出现不合理的共同平台疑似图例或人工水平线:轨迹出现不合理的共同平台
查看结果
其他 Figure(1,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

FIG 1.FIG 1. CONSORT flow diagram. a Other includes required study drug interruption longer than allowed per protocol, additional primary malignancy, noncompliance with study drug, loss to follow-up, and unspecified other reason. b Two patients who were randomly assigned to the placebo group but received darolutamide are analyzed in the darolutamide group for the safety analysis set. ADT, androgen deprivation therapy.
非 KM Figure